☆ 4.3 Article

Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features

JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Obstetrics & Gynecology

Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma

Mary Anne Brett et al.

Summary: TP53 status is crucial in endometrial carcinoma prognosis, with mutated p53 EEC3 and ESC showing a poorer outcome compared to wild-type EEC3. However, when adjusted for various factors, survival between ESC and p53 mutated EEC3 did not significantly differ. The overlap in survival between p53 mutated EEC3 and ESC, particularly in MMR-deficient cases, suggests the importance of MMR status in determining prognosis.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)

添加到收藏夹

Article Pathology

Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features

Amy Joehlin-Price et al.

Summary: This study evaluated the prognostic impact of molecular classification on FIGO grade 3 endometrioid endometrial carcinoma, using POLE mutation analysis and immunohistochemistry. The POLE mutation group and multiple classifier group showed excellent clinical outcomes, while the p53-ab group showed the worst clinical outcomes. Overall, there was no correlation between molecular grouping and tumor immunophenotypic findings.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)

添加到收藏夹

Article Pathology

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang et al.

Summary: The study confirmed the ability of TP53 IHC to predict TP53 mutation status in ovarian mucinous tumors and showed that TP53 mutation is associated with a higher risk of mortality in MBOT patients.

MODERN PATHOLOGY (2021)

添加到收藏夹

Article Oncology

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Nicole Concin et al.

Summary: The European consensus conference on endometrial carcinoma in 2014 aimed to produce multi-disciplinary evidence-based guidelines. Since then, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) have decided to update the guidelines and cover new topics to improve care for women with endometrial carcinoma globally.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Article Obstetrics & Gynecology

The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting

Martin Koebel et al.

Summary: p53 IHC is a reliable diagnostic adjunct for histotyping and molecular subtyping of ovarian and endometrial carcinomas, particularly important in identifying high-risk neoplasms. Familiarity with interpretation of p53 IHC is crucial for practicing gynecological pathologists, but further refinement of interpretation criteria is needed for different tumor sites.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)

添加到收藏夹

Review Oncology

p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification

Amy Jamieson et al.

Summary: Our understanding of endometrial cancer has evolved from clinicopathologic classifications to molecular subtypes, with a focus on the p53abn endometrial cancer subgroup associated with high mortality and poor clinical outcomes. Identifying molecular characteristics beyond TP53 mutations is essential for improving treatment options for these aggressive cancers.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Article Oncology

Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis

Jessica N. McAlpine et al.

Summary: Endometrial cancers with pathogenic POLE mutations are not associated with traditional risk parameters, and patients do not seem to benefit from adjuvant therapy. Low rates of recurrence/progression and high salvage rates may allow for safely decreasing treatment intensity for these patients.

CANCER (2021)

添加到收藏夹

Letter Oncology

Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?

Anna Merlotti et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Article Oncology

Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer

Sara Imboden et al.

Summary: A study applied new risk grouping guidelines incorporating molecular and clinicopathologic parameters for endometrial cancer patients, showing significant survival differences. Some patients experienced a change in risk group due to P53 abnormalities or POLE mutations, requiring specific cases to undergo TP53 and MMR immunohistochemistry as well as POLE sequencing.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis

Jessica N. McAlpine et al.

Summary: Patients with ECs harboring pathogenic POLE mutations do not benefit from adjuvant therapy, as these mutations are not associated with most traditional risk parameters, and they exhibit low rates of adverse events with high and sustained salvage rates in cases of recurrence.

CANCER (2021)

添加到收藏夹

Article Pathology

SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma

Basile Tessier-Cloutier et al.

Summary: This study revealed that SWI/SNF-deficient DDEC/UEC have higher rates of extrauterine disease spread and lower survival rates compared to SWI/SNF-intact DDEC/UEC, with poor response to conventional chemotherapy.

JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2021)

添加到收藏夹

Article Oncology

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies

Naveena Singh et al.

JOURNAL OF PATHOLOGY (2020)

添加到收藏夹

Article Oncology

Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas

Alicia Leon-Castillo et al.

JOURNAL OF PATHOLOGY (2020)

添加到收藏夹

Article Oncology

Interpretation of somatic POLE mutations in endometrial carcinoma

Alicia Leon-Castillo et al.

JOURNAL OF PATHOLOGY (2020)

添加到收藏夹

Article Oncology

Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma

Pauline Kraemer et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Alicia Leon-Castillo et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Obstetrics & Gynecology

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility

Martin Kobel et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)

添加到收藏夹

Article Oncology

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study

Melina Arnold et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Pathology

Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon

Nick Baniak et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)

添加到收藏夹

Article Obstetrics & Gynecology

High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations

Rajmohan Murali et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)

添加到收藏夹

Article Pathology

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups

Tjalling Bosse et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)

添加到收藏夹

Article Oncology

Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series

S. Kommoss et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Letter Oncology

Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538-549

Martin Kobel et al.

JOURNAL OF PATHOLOGY (2018)

添加到收藏夹

Review Oncology

The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses

Jessica McAlpine et al.

JOURNAL OF PATHOLOGY (2018)

添加到收藏夹

Article Pathology

Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup

Lien N. Hoang et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)

添加到收藏夹

Article Pathology

Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases

Martin Koebel et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)

添加到收藏夹

Article Pathology

Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas

Mackenzie Coatham et al.

MODERN PATHOLOGY (2016)

添加到收藏夹

Article Pathology

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma

Martin Kobel et al.

JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2016)

添加到收藏夹

Article Oncology

Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers

Alon D. Altman et al.

GYNECOLOGIC ONCOLOGY (2015)

添加到收藏夹

Article Pathology

Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations

Yaser R. Hussein et al.

MODERN PATHOLOGY (2015)

添加到收藏夹

Article Oncology

POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium

Bo Meng et al.

GYNECOLOGIC ONCOLOGY (2014)

添加到收藏夹

Article Pathology

Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas

Lien N. Hoang et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)

添加到收藏夹

Article Pathology

Reproducibility of histological cell type in high-grade endometrial carcinoma

Guangming Han et al.

MODERN PATHOLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Integrated genomic characterization of endometrial carcinoma

Gad Getz et al.

NATURE (2013)

添加到收藏夹

Article Medicine, General & Internal

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma:: multicentre randomised trial

CL Creutzberg et al.

LANCET (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.